Superbug Bolts the Door on a Last-Resort Antibiotic
Swiss researchers say the hospital pathogen Pseudomonas aeruginosa plugs the channels imipenem uses to get inside, using a small protein triggered by copper and zinc. The mechanism could become a target for drugs that hold the door open, but that is still a hope, not a treatment.
Researchers at the University of Geneva say they have found how a dangerous hospital bacterium shuts out imipenem, an antibiotic doctors keep for their sickest patients, and that it can do so far faster than anyone had shown.
The bacterium is Pseudomonas aeruginosa. The team, led by Karl Perron with Verena Ducret as first author, reports that a small protein called PtrA blocks the entrance of the channels the drug needs to get inside. The work appeared in the Proceedings of the National Academy of Sciences under the title "A periplasmic regulator establishes adaptive impermeability to control carbapenem entry" [1].
A door in the wall
Imipenem belongs to the carbapenems, antibiotics held back for infections that other drugs cannot treat. To work, it has to get inside the bacterial cell. Pseudomonas aeruginosa wears a double wall, two membranes with a gap between them called the periplasm. Imipenem crosses the outer wall through a channel known as the OprD porin [1][3].
The familiar way for the bacterium to resist is to build fewer of those channels. Fewer doors, fewer drug molecules getting in. That takes time, because the cell has to change what it manufactures.
The Geneva team describes a faster layer beneath it. According to the researchers, PtrA sits in the periplasm and attaches to protein complexes that contain OprD. There it blocks the channel entrance to imipenem [1][3]. The doors are still in the wall, but something has been jammed in the doorway.
Ducret named the process "adaptive impermeability" [1][3].
Copper, zinc, and two stages
The researchers say the response runs in two steps, and copper and zinc set it off. First PtrA moves in and blocks the OprD channels already in place. Only afterwards does the bacterium cut back on making OprD [1][3].
The order matters. The bacterium can become more resistant to imipenem before the amount of OprD has fallen at all [1][3]. A bacterium with a full set of channels may still be shut tight.
The sequence reads like an emergency measure followed by a permanent one. Plugging channels that already exist asks nothing of the cell's factory, so it can come first. Rebuilding the wall with fewer doors is the slower job that follows.
That reading is the paper's own, the researchers describe the two stages and what triggers them.
That is a problem for how resistance is detected. Perron said the finding suggests that methods which measure how much OprD a bacterium carries, or which look for mutations, may miss this form of resistance [1][3]. A test that counts doors would report an open house.
Why this bacterium matters
Pseudomonas aeruginosa is a cause of healthcare-associated infections. According to the US Centers for Disease Control and Prevention, it hits hospital patients and people with weakened immune systems in particular [2].
The CDC's Antimicrobial Resistance Lab Network offers a sense of how tangled carbapenem resistance in this species is. Of 109,533 carbapenem-resistant isolates tested from 2017 to 2024, 2.6 percent had at least one of five targeted carbapenemase genes, roughly 2,800 isolates [2].
Carbapenemases are enzymes that chew up the drug after it gets in. That leaves more than 106,000 resistant isolates over eight years without any of those five genes, so other defences, including keeping the drug out, are in play.
The CDC warns that its isolates are a convenience sample and that the network is not traditional surveillance [2]. The figure shows a pattern in what labs sent in, not a national count.
What is not shown
The Geneva group used genetic and biochemical experiments, and the study summaries give no sample counts [1][3]. Nothing in them shows that PtrA blocks imipenem in a patient. Whether the mechanism operates in infected people, and how much it adds to resistance compared with the slower fall in OprD and other defences, has not been reported.
The researchers themselves frame the next steps as questions. Do other disease-causing bacteria have a similar immediate defence? Could such mechanisms eventually be disabled to bring antibiotics back into play [1][3]?
The idea behind the hope
Most drug design against resistant bacteria chases the enzymes that destroy antibiotics. A blocker that works at the entrance suggests a different target, a small protein that has to touch a known channel to do its job. If a drug could stop PtrA from reaching OprD, imipenem might get back in. That would be a way to rescue an existing antibiotic rather than invent a new one.
It is a hypothesis, and a reasonable one. No one has yet reported disabling PtrA or showing that doing so restores imipenem's effect. If a bacterium can be resistant while carrying its usual number of channels, labs that rely on counting channels or scanning for mutations have a blind spot. A report of normal OprD levels would no longer settle whether imipenem can get through, and the Geneva work gives labs a reason to look for the difference.
The more immediate payoff may be diagnostic.
The next test is whether other labs find PtrA doing the same thing in clinical isolates, and whether other pathogens turn out to have their own door-bolting proteins.
Every edition in brief, three times a day, on our Telegram channel, on Bluesky and on Threads.




